中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 6
Jun.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(6): 1126-1129

Correlation of serum angiopoietin-1， angiopoietin-2， and angiopoietin-1/angiopoietin-2 ratio with HBV DNA and alanine aminotransferase in patients with chronic hepatitis B or liver cirrhosis

DOI: 10.12449/JCH240609
  • 1.

    Beijing YouAn Hospital，Beijing Institute of Liver Diseases，Capital Medical University，Beijing 100069，China

  • 2.

    Department of Clinical Laboratory，Liaocheng People’s Hospital，Liaocheng，Shandong 252000，China

Research funding:

Beijing Municipal Institute of Public Medical Research Development and Reform Pilot Project (JING YI YAN 2021-10);

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer (BG0320)

More Information
  • Corresponding author: LIN Minghua， minghualin@ccmu.edu.cn （ORCID： 0000-0003-1220-461X）
  • Received Date: 2023-08-22
  • Accepted Date: 2023-11-16
  • Published Date: 2024-06-25
    Abstract
  •   Objective  To investigate the correlation of serum angiopoietin-1 （Ang-1）， angiopoietin-2 （Ang-2）， and Ang-1/Ang-2 ratio with HBA DNA and alanine aminotransferase （ALT） in patients with chronic hepatitis B （CHB） or liver cirrhosis.  Methods  Clinical data and serum specimens were collected from 99 patients with CHB and 59 patients with liver cirrhosis who were admitted to Beijing YouAn Hospital， Capital Medical University， from March 2018 to October 2019， and 46 individuals who underwent physical examination were enrolled as control group. PCR was used to measure serum HBV DNA level， and ELISA was used to measure the serum levels of Ang-1 and Ang-2. The serum levels of Ang-1 and Ang-2 and Ang-1/Ang-2 ratio were compared between groups. The Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups， and the Bonferroni method was used for further comparison between two groups； the Spearman correlation analysis was used to investigate the correlation of Ang-1， Ang-2， and Ang-1/Ang-2 ratio with HBV DNA and ALT.  Results  Compared with the control group， the CHB group and the liver cirrhosis group had a significant reduction in the level of Ang-1 （479.0 pg/mL and 208.4 pg/mL vs 671.0 pg/mL， both P<0.05）， and compared with the CHB group， the liver cirrhosis group had a significant reduction in the level of Ang-1 （P<0.001）. Compared with the control group， the CHB group and the liver cirrhosis group had a significant increase in the level of Ang-2 （286.1 pg/mL and 438.4 pg/mL vs 198.0 pg/mL， both P<0.001）， and compared with the CHB group， the liver cirrhosis group had a significant increase in the level of Ang-2 （P<0.001）. Compared with the control group， the CHB group and the liver cirrhosis group had a significant reduction in Ang-1/Ang-2 ratio （1.6 and 0.5 vs 3.4， both P<0.001）， and compared with the CHB group， the liver cirrhosis group had a significant reduction in Ang-1/Ang-2 ratio （P<0.001）. The Spearman correlation analysis showed that in the CHB group， Ang-1 was negatively correlated with HBV DNA and ALT （r=-0.400 and -0.394， both P˂0.001）， Ang-2 was positively correlated with HBV DNA and ALT （r=0.365 and 0.351， both P<0.001）， and Ang-1/Ang-2 ratio was negatively correlated with HBV DNA and ALT （r=-0.463 and -0.473， both P<0.001）； in the liver cirrhosis group， Ang-1， Ang-2， and Ang-1/Ang-2 ratio had no correlation with HBV DNA or ALT （all P>0.05）.  Conclusion  There are significant changes in the serum levels of Ang-1 and Ang-2 and Ang-1/Ang-2 ratio in patients with CHB or liver cirrhosis， and Ang-1， Ang-2， and Ang-1/Ang-2 ratio reflects the degree of liver injury in patients with CHB to a certain extent.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    SAHARINEN P, LEPPÄNEN VM, ALITALO K. SnapShot: Angiopoietins and their functions[J]. Cell, 2017, 171( 3): 724- 724. DOI: 10.1016/j.cell.2017.10.009.
    [2]
    JEANSSON M, GAWLIK A, ANDERSON G, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury[J]. J Clin Invest, 2011, 121( 6): 2278- 2289. DOI: 10.1172/JCI46322.
    [3]
    LEE SJ, LEE CK, KANG S, et al. Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction[J]. J Clin Invest, 2018, 128( 11): 5018- 5033. DOI: 10.1172/JCI99659.
    [4]
    MELENDEZ E, WHITNEY JE, NORTON JS, et al. Systemic angiopoietin-1/2 dysregulation in pediatric sepsis and septic shock[J]. Int J Med Sci, 2019, 16( 2): 318- 323. DOI: 10.7150/ijms.27731.
    [5]
    KUMAR NP, VELAYUTHAM B, NAIR D, et al. Angiopoietins as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2017, 21( 1): 93- 99. DOI: 10.5588/ijtld.16.0565.
    [6]
    van MEURS M, KÜMPERS P, LIGTENBERG JJ, et al. Bench-to-bedside review: Angiopoietin signalling in critical illness-a future target?[J]. Crit Care, 2009, 13( 2): 207. DOI: 10.1186/cc7153.
    [7]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [8]
    PARIKH SM. Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS[J]. Virulence, 2013, 4( 6): 517- 524. DOI: 10.4161/viru.24906.
    [9]
    FAILLACI F, MARZI L, CRITELLI R, et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after hepatitis C virus direct-acting antivirals[J]. Hepatology, 2018, 68( 3): 1010- 1024. DOI: 10.1002/hep.29911.
    [10]
    UEHARA M, ENOMOTO N, MIKAMO M, et al. Impact of angiopoietin-1 and-2 on clinical course of idiopathic pulmonary fibrosis[J]. Respir Med, 2016, 114: 18- 26. DOI: 10.1016/j.rmed.2016.03.001.
    [11]
    LIN MH, SHI Y, XIE F, et al. Research progress of angiogenesis in liver fibrosis[J]. Beijing Med J, 2014, 36( 6): 468- 470. DOI: 10.15932/j.0253-9713.2014.06.031.

    林明华, 石英, 谢放, 等. 血管生成在肝纤维化中的研究进展[J]. 北京医学, 2014, 36( 6): 468- 470. DOI: 10.15932/j.0253-9713.2014.06.031.
    [12]
    SAHARINEN P, EKLUND L, ALITALO K. Therapeutic targeting of the angiopoietin-TIE pathway[J]. Nat Rev Drug Discov, 2017, 16( 9): 635- 661. DOI: 10.1038/nrd.2016.278.
    [13]
    PAUTA M, RIBERA J, MELGAR-LESMES P, et al. Overexpression of angiopoietin-2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition[J]. Liver Int, 2015, 35( 4): 1383- 1392. DOI: 10.1111/liv.12505.
    [14]
    LEFERE S, van de VELDE F, HOORENS A, et al. Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease[J]. Hepatology, 2019, 69( 3): 1087- 1104. DOI: 10.1002/hep.30294.
    [15]
    WHITEHEAD M, OSBORNE A, WIDDOWSON PS, et al. Angiopoietins in diabetic retinopathy: Current understanding and therapeutic potential[J]. J Diabetes Res, 2019, 2019: 5140521. DOI: 10.1155/2019/5140521.
    [16]
    YU XL, YE FC. Role of angiopoietins in development of cancer and neoplasia associated with viral infection[J]. Cells, 2020, 9( 2): 457. DOI: 10.3390/cells9020457.
    [17]
    KHANANI AM, RUSSELL MW, AZIZ AA, et al. Angiopoietins as potential targets in management of retinal disease[J]. Clin Ophthalmol, 2021, 15: 3747- 3755. DOI: 10.2147/OPTH.S231801.
    [18]
    COLLAZOS-ALEMÁN JD, GNECCO-GONZÁLEZ S, JARAMILLO-ZARAMA B, et al. The role of angiopoietins in neovascular diabetes-related retinal diseases[J]. Diabetes Ther, 2022, 13( 11-12): 1811- 1821. DOI: 10.1007/s13300-022-01326-9.
    [19]
    ZHANG HM, ZHAO ZB, XIONG YX, et al. Research progress of angiopoietins in hepatocellular carcinoma[J]. J Clin Hepatol, 2011, 27( 4): 433- 436. DOI: 10.3969/j.issn.1001-5256.2011.04.030.

    张华敏, 赵正斌, 熊亚星, 等. 血管生成素在肝细胞癌中的研究进展[J]. 临床肝胆病杂志, 2011, 27( 4): 433- 436. DOI: 10.3969/j.issn.1001-5256.2011.04.030.
    [20]
    FIEDLER U, REISS Y, SCHARPFENECKER M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation[J]. Nat Med, 2006, 12( 2): 235- 239. DOI: 10.1038/nm1351.
    [21]
    LE CRAS TD, MOBBERLEY-SCHUMAN PS, BROERING M, et al. Angiopoietins as serum biomarkers for lymphatic anomalies[J]. Angiogenesis, 2017, 20( 1): 163- 173. DOI: 10.1007/s10456-016-9537-2.
    [22]
    HERNÁNDEZ-BARTOLOMÉ Á, LÓPEZ-RODRÍGUEZ R, BORQUE MJ, et al. Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C[J]. World J Gastroenterol, 2016, 22( 44): 9744- 9751. DOI: 10.3748/wjg.v22.i44.9744.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (232) PDF downloads(48) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return